The knowns and unknowns of teprotumumab for thyroid eye disease

Lancet Diabetes Endocrinol. 2021 Jun;9(6):323-325. doi: 10.1016/S2213-8587(21)00076-0. Epub 2021 Apr 15.

Authors

Tomasz Bednarczuk¹, Simon H Pearce²

Affiliations

¹ Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 02-097, Warsaw, Poland. Electronic address: tbednarczuk@wum.edu.pl.
² Department of Endocrinology, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.

PMID: 33865499
DOI: 10.1016/S2213-8587(21)00076-0

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Data Analysis*
Follow-Up Studies
Graves Ophthalmopathy* / drug therapy
Humans

Substances

Antibodies, Monoclonal, Humanized
teprotumumab

Grants and funding

MR/V005898/1/MRC_/Medical Research Council/United Kingdom